Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis
Disha Thakkar,1 Ranjeet Prasad Dash2,31Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research-Ahmedabad, Gandhinagar, Gujarat, India; 2Drug Metabolism and Pharmacokinetics, Johns Hopkins Drug Discovery Program, Johns Hopkins University, 3Department of Neur...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-04-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/letter-httpswwwdovepresscompharmacokinetic-interactions-bet-peer-reviewed-article-DDDT |
| _version_ | 1811294169978634240 |
|---|---|
| author | Thakkar D Dash RP |
| author_facet | Thakkar D Dash RP |
| author_sort | Thakkar D |
| collection | DOAJ |
| description | Disha Thakkar,1 Ranjeet Prasad Dash2,31Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research-Ahmedabad, Gandhinagar, Gujarat, India; 2Drug Metabolism and Pharmacokinetics, Johns Hopkins Drug Discovery Program, Johns Hopkins University, 3Department of Neurology, Johns Hopkins University, Baltimore, MD, USA The topic of polymorphism in drug metabolizing enzymes and drug transporters with their impact on pharmacotherapy is of great interest. The clinical relevance depends on the vectorial movement, the therapeutic index of the substrates and inherent interindividual variability.1 With respect to the variability, various polymorphisms associated with the drug transporters have been reported that led to the alteration in the pharmacokinetic and pharmacodynamic profile of the drugs.2 Many preclinical and clinical studies have provided the evidence for the application of genetic information for the development of individualized therapies.3 View the original paper by Kim CO and colleagues. |
| first_indexed | 2024-04-13T05:13:27Z |
| format | Article |
| id | doaj.art-0cb61b8828b34692b97fb4650515814a |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-04-13T05:13:27Z |
| publishDate | 2017-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-0cb61b8828b34692b97fb4650515814a2022-12-22T03:00:58ZengDove Medical PressDrug Design, Development and Therapy1177-88812017-04-01Volume 111263126532491Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysisThakkar DDash RPDisha Thakkar,1 Ranjeet Prasad Dash2,31Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research-Ahmedabad, Gandhinagar, Gujarat, India; 2Drug Metabolism and Pharmacokinetics, Johns Hopkins Drug Discovery Program, Johns Hopkins University, 3Department of Neurology, Johns Hopkins University, Baltimore, MD, USA The topic of polymorphism in drug metabolizing enzymes and drug transporters with their impact on pharmacotherapy is of great interest. The clinical relevance depends on the vectorial movement, the therapeutic index of the substrates and inherent interindividual variability.1 With respect to the variability, various polymorphisms associated with the drug transporters have been reported that led to the alteration in the pharmacokinetic and pharmacodynamic profile of the drugs.2 Many preclinical and clinical studies have provided the evidence for the application of genetic information for the development of individualized therapies.3 View the original paper by Kim CO and colleagues. https://www.dovepress.com/letter-httpswwwdovepresscompharmacokinetic-interactions-bet-peer-reviewed-article-DDDTSLCO1B1CYP2C9genetic polymorphismpharmacokinetics |
| spellingShingle | Thakkar D Dash RP Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis Drug Design, Development and Therapy SLCO1B1 CYP2C9 genetic polymorphism pharmacokinetics |
| title | Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis |
| title_full | Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis |
| title_fullStr | Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis |
| title_full_unstemmed | Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis |
| title_short | Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions? Observations and introspection of the bioanalysis |
| title_sort | pharmacokinetic interactions between glimepiride and rosuvastatin in healthy korean subjects does the slco1b1 or cyp2c9 genetic polymorphism affect these drug interactions observations and introspection of the bioanalysis |
| topic | SLCO1B1 CYP2C9 genetic polymorphism pharmacokinetics |
| url | https://www.dovepress.com/letter-httpswwwdovepresscompharmacokinetic-interactions-bet-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT thakkard pharmacokineticinteractionsbetweenglimepirideandrosuvastatininhealthykoreansubjectsdoestheslco1b1orcyp2c9geneticpolymorphismaffectthesedruginteractionsobservationsandintrospectionofthebioanalysis AT dashrp pharmacokineticinteractionsbetweenglimepirideandrosuvastatininhealthykoreansubjectsdoestheslco1b1orcyp2c9geneticpolymorphismaffectthesedruginteractionsobservationsandintrospectionofthebioanalysis |